Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron's stock price has fluctuated, trading around $714.89 as of May 8, 2026, down 7.82% over the past 30 days but up 30.53% over the past 12 months. Recent events include the first-quarter 2026 earnings report with revenue of US$3,605.4 million and net income of US$727.2 million, affirmation of a quarterly dividend of US$0.94 per share, completion of a US$2.31 billion buyback, authorization of a new US$3.00 billion share repurchase program, FDA approvals expanding Dupixent and granting accelerated approval for Otarmeni, competition and pricing pressure on Eylea, and new data supporting Dupixent's potential use in COPD.

Information regarding the seasonality of demand for Regeneron Pharmaceuticals' products and services is not explicitly detailed. The available information primarily discusses the historical seasonal performance of REGN stock, indicating recurring monthly trends in the asset's performance. However, these patterns reflect past stock data and may not predict future performance or directly correlate with the seasonality of product demand.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. Founded in 1988, it operates using its VelociSuite® technologies, including VelocImmune® and the Regeneron Genetics Center®. Key products include Eylea and Eylea HD for eye diseases, Dupixent for allergic and inflammatory conditions, Libtayo for cancers, Kevzara for rheumatoid arthritis, Praluent for cholesterol lowering, Arcalyst for autoinflammatory conditions, Zaltrap for colorectal cancer, Inmazeb for Ebola, Evkeeza for hypercholesterolemia and Otarmeni for OTOF-related hearing loss.

Regeneron Pharmaceuticals has a global presence with over 15,400 employees across 12 countries and clinical trials in more than 50 countries. Its headquarters are in Tarrytown, New York, with biologics facilities in Rensselaer, New York, and Limerick, Ireland. It also has offices in other North American cities, Dublin, London, Amsterdam, Madrid, Milan, Munich and Paris.

Regeneron Pharmaceuticals has a strong brand reputation due to its commitment to science and innovative medicines. The company has received accolades such as being named to the Dow Jones Best-in-Class World Index and North America Index, Newsweek's America's Most Responsible Companies, and TIME's World's Most Sustainable Companies. Its commitment to patient access, exemplified by providing Otarmeni for free in the United States, and its STEM-Fueled™ initiative further enhance its reputation.

Regeneron Pharmaceuticals' ownership includes significant institutional investors, public shareholders, and insider holdings. Major institutional owners include The Vanguard Group, Inc., BlackRock Institutional Trust Company, N.A., State Street Investment Management (US), Dodge & Cox, JP Morgan Asset Management and Geode Capital Management, LLC. Sanofi is the largest individual shareholder, owning 34.83% of the company. Founders Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos also maintain substantial ownership.